Trimel Pharma's sexual disorder drug effective in mid-stage study
May 28 (Reuters) - Trimel Pharmaceuticals Corp said its experimental sexual disorder drug increased the average number of orgasms in patients with Female Orgasmic Disorder in a mid-stage study.
The company said a 0.6 mg dose of the nasal drug, Tefina, showed a statistically significant increase in the number of orgasms in pre-menopausal and post-menopausal patients with the condition, compared with a placebo.
Female Orgasmic Disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, leading to distress. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video